Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: meta-analyses of published studies
arXiv:1608.04300 · doi:10.1016/j.cct.2016.12.004
Abstract
Purpose: PFS is often used as a surrogate endpoint for OS in metastatic breast cancer studies. We have evaluated the association of treatment effect on PFS with significant HR (and how this association is affected by other factors) in published prospective metastatic breast cancer studies. Methods: A systematic literature search in PubMed identified prospective metastatic breast cancer studies. Treatments effects on PFS were determined using hazard ratio (HR), increase in median PFS (MED) and % increase in median PFS (%MED). Diagnostic accuracy of PFS measures (HR, MED and %MED) in predicting significant HR was assessed using receiver operating characteristics (ROC) curves and classification trees approach. Results: Seventy-three cases (i.e., treatment to control comparisons) from 64 individual publications were identified for the analyses. Of these, 16 cases reported significant treatment effect on HR at 5% level of significance. Median number of deaths reported in these cases were 156. Area under the ROC curve (AUC) for diagnostic measures as HR, MED and %MED were 0.69, 0.70 and 0.75, respectively. Classification tree results identified %MED and number of deaths as diagnostic measure for significant HR. Only 7.9\% (3/39) cases with MED shorter than 48.27\% reported significant HR. There were 7 cases with MED of 48.27\% or more and number of deaths reported as 227 or more -- of these 5 cases reported significant HR. Conclusion: %MED was found as better diagnostic measure for significant HR. Our analysis results also suggest that consideration of total number of deaths may further improve its diagnostic performance.